Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sierra Oncology Inc
(NQ:
SRRA
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jun 30, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Sierra Oncology Inc
< Previous
1
2
Next >
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration
June 17, 2022
From
Sierra Oncology
Via
Business Wire
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
May 26, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting
May 12, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Reports First Quarter 2022 Results
May 06, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 05, 2022
From
Sierra Oncology
Via
Business Wire
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
May 02, 2022
From
Kuznicki Law PLLC
Via
Business Wire
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
April 25, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
April 14, 2022
Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically...
Via
FinancialNewsMedia
SRRA Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Sierra Oncology, Inc. Is Fair to Shareholders
April 13, 2022
From
Halper Sadeh LLP
Via
Business Wire
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
April 13, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 06, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 18, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 04, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 03, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology to Participate in Guggenheim Oncology Conference
February 03, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Closing of Upsized Public Offering of $135.0 Million of Securities
January 31, 2022
From
Sierra Oncology
Via
Business Wire
R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments
January 27, 2022
Palm Beach, FL – January 27, 2022 – FinancialNewsMedia.com News Commentary – According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018,...
Via
FinancialNewsMedia
Topics
Death
Intellectual Property
Exposures
Death
Intellectual Property
Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference
January 27, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Pricing of Upsized Public Offering of Securities
January 26, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Proposed Public Offering of Common Stock
January 25, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib
January 25, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis
January 25, 2022
From
Sierra Oncology
Via
Business Wire
Momelotinib Review Article Published in Journal of Hematology & Oncology Highlights Importance of Anemia Benefit for Myelofibrosis Patients
January 19, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Updates Topline Data Timing for Pivotal Phase 3 Trial of Momelotinib in Myelofibrosis
January 18, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 07, 2022
From
Sierra Oncology
Via
Business Wire
Sierra Oncology to Present at HC Wainwright BioConnect Conference
January 05, 2022
From
Sierra Oncology, Inc.
Via
Business Wire
Sierra Oncology Reports Baseline Ferritin Differentially Predicts Week 24 Transfusion Independence Response in Myelofibrosis Patients
December 13, 2021
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Investor Event to Review MOMENTUM Trial Design and Available Phase 3 Momelotinib Data in Myelofibrosis
December 06, 2021
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 03, 2021
From
Sierra Oncology
Via
Business Wire
Sierra Oncology Announces Presentation at Jefferies London Healthcare Conference
November 12, 2021
From
Sierra Oncology
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.